A Phase III, observer-blind, randomised, controlled, multi-centre study to evaluate the immunogenicity and safety of GSK Biologicals? quadrivalent influenza vaccine candidate, GSK2282512A (FLU Q-QIV), compared to Sanofi Pasteur?s quadrivalent influenza v

  • Sarpong, Kwabena, (PI)

Project: Other project

StatusFinished
Effective start/end date10/7/1410/6/16

Funding

  • GlaxoSmithKline Pharmaceuticals: $2,884.62